Press Releases

Press Releases

Date Title  
Sep 15, 2022 Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
-- Reduction in Mortality Risk with Narsoplimab -- SEATTLE --(BUSINESS WIRE)--Sep. 15, 2022-- Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC).
Sep 15, 2022 I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
SAN FRANCISCO & SEATTLE --(BUSINESS WIRE)--Sep. 15, 2022-- Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent narsoplimab, announced that enrollment has been closed and data have been analyzed
Aug 17, 2022 Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
SEATTLE --(BUSINESS WIRE)--Aug. 17, 2022-- Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by
Aug 09, 2022 Omeros Corporation Reports Second Quarter 2022 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 9, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
Aug 04, 2022 Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
SEATTLE --(BUSINESS WIRE)--Aug. 4, 2022-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2022 , on Tuesday, August 9, 2022 , after the market closes. Omeros management will host a conference call and
Jul 29, 2022 FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
- - Enrollment of PNH Patients Expected to Begin this Summer -- SEATTLE --(BUSINESS WIRE)--Jul. 29, 2022-- Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria
Jun 15, 2022 Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE --(BUSINESS WIRE)--Jun. 15, 2022-- Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, June 17, 2022 , starting at 10:00 a.m. Pacific Time .
May 10, 2022 Omeros Corporation Reports First Quarter 2022 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 10, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
May 04, 2022 Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
SEATTLE --(BUSINESS WIRE)--May 4, 2022-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022 , on Tuesday, May 10, 2022 , after the market closes. Omeros management will host a conference call and
Apr 20, 2022 Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
SEATTLE --(BUSINESS WIRE)--Apr. 20, 2022-- Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic
Mar 01, 2022 Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2022-- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
Feb 24, 2022 Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
SEATTLE --(BUSINESS WIRE)--Feb. 24, 2022-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021 , on Tuesday, March 1, 2022 , after the market closes.
Jan 19, 2022 Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
SEATTLE --(BUSINESS WIRE)--Jan. 19, 2022-- Omeros Corporation (Nasdaq: OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency’s Complete Response Letter (CRL) for narsoplimab in the treatment of hematopoietic